On December 18, 2020 Juventas Cell Therapy reported in just two years since its establishment in 2018, Heyuan Biotech has made breakthroughs in clinical transformation and commercialization platform construction, product development and pipeline layout, process and quality system construction, and team building (Press release, Juventas Cell Therapy, DEC 18, 2020, View Source [SID1234633520]). The first drug with independent knowledge The proprietary product CNCT19 cell injection was recognized as a "Breakthrough Therapy Drug" by the State Drug Administration in December 2020. It is the first CAR-T product in the field of leukemia in China that has reached the end point of clinical research, and it is also expected to become the first. A domestically-independent innovative CAR-T product targeting the CD19 target.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

At the same time, the company continues to build a highly scalable and internationally competitive innovation pipeline, quickly achieving coverage of blood tumor pipelines, solid tumor pipelines and forward-looking general platform pipelines.